All In MedTech

FDA Clearance Tracker · P130026-S069

TactiCath Quartz Contact Force Ablation Catheter

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 3, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 3, 2021

Approved

Time to decision

179 days

Received Feb 5, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P130026-S069
Device name
TactiCath Quartz Contact Force Ablation Catheter
Applicant location
St. Paul, MN
Received
Feb 5, 2021
Decided
Aug 3, 2021
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P130026

Device type

Device class
Class III

Every decision under product code OAE

FDA's approval statement

As written in FDA's record.

Approval for a labeling update for the TactiCath Quartz Contact Force Ablation Catheter Instructions for Use to included a summary of the long-term effectiveness data from the TactiCath Quartz Post-Approval Study.

Source documents

Other decisions for St Jude Medical

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.